Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYtech Pharma has been awarded ISO 9001:2008 Certification
Lyon (France), Philadelphia (USA), November 24 2009. ERYtech Pharma has been awarded ISO9001:2008 Certification. The International Organization for Standardization is the world’s leading International Standards developer. ISO 9001:2008 specifies the requirements which have been fulfilled by
View HTML
Toggle Summary ERYTECH Pharma and Genzyme Corporation sign collaborative research agreement in rare diseases
Lyon (France) – October 12th, 2010 ERYtech Pharma is pleased to announce it has signed a collaborative research agreement with Genzyme Corporation to explore the feasibility of developing a novel therapeutic enzyme formulation using ERYtech’s proprietary technology.
View HTML
Toggle Summary ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer
LYON, France & PHILADELPHIA--( BUSINESS WIRE )-- The first clinical trial using Graspa® on a solid tumor. A good safety profile for Graspa® in last-line therapy patients. A major step forward in its flagship product deployment in solid tumors. ERYTECH Pharma has just completed the enrollment of
View HTML
Toggle Summary ERYTECH Pharma receives € 7 million from OSEO to lead the TEDAC personalized medicine project in cancer
ERYTECH Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer Financing of € 6.95 million through grants and redeemable advances from the French public organization OSEO Leader of the collaborative project that aims to create major innovations within a
View HTML
More >>

Upcoming Events

Date Event Details
Summary ToggleNov 13, 2018 at 2:30 PM CET

Erytech Pharma Third Quarter 2018 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top